P

Pharvaris NV
D

PHVS

16.180
USD
-0.37
(-2.25%)
مغلق
حجم التداول
872
الربح لكل سهم
-3
العائد الربحي
-
P/E
-6
حجم السوق
877,491,639
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: Pharvaris NV

القطاع: Healthcare
الصناعة: Biotechnology
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.